GlassScriptPhysician profile
Deanna Salyards
NPI 1174544290
$7,944.25
in general payments reported to CMS, 2019-2025
50 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $1,617 · 2023: $1,975 · 2024: $1,402 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $993.30 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $908.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $892.28 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $610.73 | 2021-2025 | |
| Lilly USA, LLC | $572.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Ironshore Pharmaceuticals INC. | $421.53 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $339.35 | 2021-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $294.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $262.83 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $249.58 | 2022 | |
| Amgen INC. | $187.41 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $176.76 | 2021-2024 | Verquvo, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.73 | 2021-2024 | Jardiance, Synjardy |
| Abbott Laboratories | $168.03 | 2021-2025 | Aveir, Assurity, Gallant |
| Novo Nordisk INC | $166.09 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Salyards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.